The safety and efficacy of auto-SCT for lymphoma in older patients is not well established, particularly in those X70 years old. We performed a retrospective analysis comparing 17 auto-SCT recipients X70 years old with 39 recipients aged 65-69 years. Hematopoietic cell transplantation comorbidity index (HCT-CI) scores were similar in both groups. Nonrelapse mortality (NRM) was increased in patients aged 70 years and older (hazard ratio (HR) 6.04, P ¼ 0.0029), and OS was decreased (HR 1.98, P ¼ 0.082). 1-year NRM was 35% in patients aged X70 years vs 8% in those aged 65-69 years (P ¼ 0.017). The incidence of in-hospital falls was higher in those aged X70 years (29 vs 8%, P ¼ 0.047). In a secondary exploratory analysis, we found that the occurrence of in-hospital falls was strongly associated with inferior OS (HR 3.36, P ¼ 0.0023) and NRM (HR 4.60, P ¼ 0.009) among all patients of aged 65 years and older. We conclude that auto-SCT is feasible in older patients but that mortality rates appear increased in those over age of 70 years. In-hospital falls were correlated with higher mortality, and prevention of falls may improve outcomes. Susceptibility to falls may indicate underlying frailty and should be explored prospectively as a means of selecting older patients for auto-SCT.
Introduction
Approximately 75 000 new cases of lymphoma are diagnosed in the United States each year. Anthracycline-based chemotherapy can cure many patients with aggressive non-Hodgkin's lymphoma, but many will suffer a relapse after achieving a complete response or will have refractory disease. For these patients, salvage chemotherapy followed by auto-SCT can be curative. 1 Auto-SCT is also widely used as consolidation or salvage therapy in mantle cell lymphoma, 2-5 peripheral T-cell lymphomas 6, 7 and Hodgkin's lymphoma. 8, 9 Clinical trials of auto-SCT for lymphoma have generally been restricted to patients under the age of 55 or 60 years, and less is known about the safety and efficacy of auto-SCT in older patients. At the same time, the incidence of lymphoma is increasing with age, with the age-adjusted incidence of lymphoma in individuals over the age of 65 years more than double that of individuals aged 50-64 years (http://seer.cancer. gov/faststats, accessed on April 16, 2010) . Because of these demographics, better characterization of the role of auto-SCT in older patients with lymphoma is needed.
Several retrospective studies have looked at outcomes of auto-SCT in patients over the age of 60 or 65 years. [10] [11] [12] [13] These have generally found similar rates of OS and modestly increased treatment-related mortality compared with younger patients. Most patients in these studies were under the age of 70 years, and there are no published reports looking specifically at those aged 70 years and over. Therefore, we evaluated the outcomes of auto-SCT in a series of patients aged 70 years and older, and compared them with a cohort aged 65-69 years. In addition, we looked for other patient characteristics other than age that might identify older patients at risk for inferior outcomes after auto-SCT.
Patients and methods

Patients
We identified 56 consecutive patients aged 65 years and older who underwent auto-SCT for lymphoma at UCLA Medical Center between 1999 and 2009. Data were collected from an institutional database and from retrospective chart review. Data collection was conducted under a protocol approved by the UCLA Institutional Review Board. Comorbidity index scoring using the Charlson Comorbidity Index (CCI) and the hematopoietic SCTspecific comorbidity index (HCT-CI) was performed retrospectively through review of the initial consultation note for transplant evaluation and the admission history and physical examination before transplantation.
Stem cell collection, conditioning regimens and supportive care Peripheral blood hematopoietic stem cells were collected by leukapheresis during recovery from chemotherapy. For mobilization, patients also received s.c. G-CSF 10 mg/kg per day until the completion of stem cell collection. Leukapheresis was begun once the ANC was 41500 cells/mL, with a target cell collection of 2 /day on days À6 to À2 and carmustine 500 mg/m 2 on day À2). Eight patients received TBI and high dose chemotherapy as follows: 150 cGy twice daily on days À8 to À5, etoposide 60 mg/kg on day À4, cyclophosphamide 100 mg/kg and mesna 100 mg/kg on day À2. Stem cells were infused on day 0.
All patients were hospitalized for conditioning and SCT. They were kept in single rooms and were given antimicrobial prophylaxis with oral nonabsorbable antibiotics, including nystatin and norfloxacin. Febrile neutropenic patients received empiric i.v. antibiotic therapy with imipenem or other broad-spectrum anti-pseudomonal antibiotics. Documented or suspected invasive fungal infections were treated with azoles (fluconazole, itraconazole, voriconazole, or posaconazole) or amphotericin B. Patients received s.c. G-CSF 5 mg/kg per day or GM-CSF 250 mg/m 2 per day starting on day þ 2 after SCT, continuing until the ANC was X1500 cells per mL for 3 consecutive days. RBCs were transfused to maintain hemoglobin X8 g/dL, and single donor platelets were transfused to maintain a platelet count of X10 Â 10 9 /L.
Patient outcomes
Data on transplant complications from the start of conditioning to day þ 100 following transplant were obtained from the medical record. Psychiatric complications were ascertained from the physicians' progress notes in which the terms 'delirium,' 'confusion' or 'altered mental status' were used. Arrhythmias were defined as all supraventricular or ventricular arrhythmias thought to be of clinical significance by the physician of record. Congestive heart failure was diagnosed by clinical assessment by the physician of record and/or on the basis of echocardiography showing a decrease in ejection fraction. Hepatic and renal toxicity were defined according to the Seattle criteria.
14 Falls were ascertained through retrospective review of progress notes and discharge summaries in the medical record. OS and nonrelapse mortality (NRM) were calculated from the date of SCT. NRM was defined as any death up to 5 years from the date of transplant in the absence of known recurrence of lymphoma. NRM was also calculated as a proportion 100 days and 1 year after transplant. Data regarding the date and cause of death were obtained from the medical record, from the treating physician and/or from the Social Security Death Index (http://ssdi.rootsweb.ancestry.com/cgi-bin/ssdi.cgi).
Statistical analysis
Analyses of OS and NRM were performed using the method of Kaplan-Meier. Comparisons of proportions between groups were performed using Fisher's exact test, or w 2 when there were more than two possible outcomes.
Comparisons of continuous variables between groups, such as length of stay and time to neutrophil engraftment, were performed using nonparametric methods (Mann-Whitney U-test). All analyses were unadjusted given the small size of the cohort. All P-values were two-sided. Statistical analysis was performed using GraphPad Prism for Windows, version 4.03 (GraphPad Software, La Jolla, CA, USA).
Results
Characteristics of the patients are shown in Table 1 . There were 39 patients aged 65-69 years and 17 patients aged 70 years and above. There were more men in the 65-69-year old cohort (72 vs 47%), though this was not statistically significant. Disease status at transplant and diagnosis were Response to most recent chemotherapy
Abbreviations: CCI ¼ Charlson Comorbidity Index; DLBCL ¼ diffuse large B cell lymphoma; HCT-CI ¼ hematopoietic SCT-specific comorbidity index; PD ¼ progressive disease; SD ¼ stable disease.
similarly proportioned in the two age groups. Approximately 70% of the patients in each group had diffuse large B-cell lymphoma. Patients aged 70 years and older were significantly more likely to be in CR at the time of auto-SCT (53 vs 18%, P ¼ 0.012). Comorbid conditions were evaluated using two scales. The CCI is the most widely used comorbidity index in oncology. 15 Most of the patients in our cohort had the lowest possible comorbidity score (0), and there was no statistically significant difference in the CCI score distribution based on age group. Similarly, there were no differences in the frequency of any of the individual illnesses that comprise the CCI. The HCT-CI is a modification of the CCI developed and validated in patients undergoing allo-SCT. 16 Using this scale, three (8%) patients aged 65-69 years and two (12%) patients aged 70 years and older had an HCT-CI score of three or greater. The majority of patients in each group had the lowest possible score of 0 (64 and 65%, respectively.) There was no significant difference in HCT-CI score between the age groups.
The median number of hematopoietic stem cells collected and the median number of days required for stem cell collection were not statistically different in the two age groups (Table 2) . For myeloablative conditioning, a small minority received TBI (13% aged 65-69 years, 18% aged X70 years, P ¼ 0.68), and the others received high dose chemotherapy alone. The median time to neutrophil engraftment (ANC 4500 cells per mL) was the same in both age groups, although statistical analysis indicated that the overall time to neutrophil engraftment was slightly longer among the older patients (P ¼ 0.01 by the nonparametric Mann-Whitney test.).
The incidence of transplant complications within the first 100 days is shown in Table 3 . Patients aged 70 years and older were more likely to suffer an in-hospital fall than those aged 65-69 years (29 vs 8%, P ¼ 0.047). Other complications, including psychiatric disturbance, admission to the intensive care unit, arrhythmia, congestive heart failure, renal failure and hepatic toxicity were more frequent in older patients, but these findings were not statistically significant. The length of hospital stay was the same (median, 21 days in both groups) and the rate of readmission to the hospital after discharge within 100 days of transplant was similar (28% aged 65-59 years and 35% aged 70 years and older).
OS curves are shown in Figure 1a . All-cause mortality at 100 days was 17.65% in patients aged 70 years and older vs 7.69% in those aged 65-69 years (P ¼ 0.354). All-cause mortality at 1 year was 41.18% in patients aged 70 years and older vs 17.95% in those aged 65-69 years (P ¼ 0.0943). The HR for death from any cause for patients aged 70 years and older was 1.98 (95% confidence interval range, 0.90-5.53, P ¼ 0.082). The median survival among patients aged 65-69 years was 6.03 years, vs 2.62 years for those aged 70 years and older.
NRM is shown in Figure 1b . NRM at 100 days was 17.65% in patients aged 70 years and older vs 5.13% in those aged 65-69 years (P ¼ 0.158). 1-year NRM was 35.29% in patients aged 70 years and older vs 7.69% in those aged 65-69 years, a difference that was statistically significant (P ¼ 0.017). The HR for NRM in patients aged 70 years and older was 6.04 (95% confidence interval 2.05-32.66, P ¼ 0.0029).
With a median 27 months of follow-up, there have been 11 deaths among the 17 patients aged 70 years and older (65%) and 19 deaths among the 39 patients aged 65-69 years(49%). The causes of death are shown in Table 4 . A total of 18% of the deaths in patients aged 70 years and older were due to lymphoma, vs 58% in those aged 65-69 years. Recurrent lymphoma was the most common cause of death in patients aged 65-69 years, whereas infection was the most common cause in those aged 70 years and older. In nine patients, the cause of death is unknown. All but two deaths of unknown cause occurred more than 3 years after transplantation.
Looking at the entire cohort of patients aged 65 years and older, we asked if there were other clinical characteristics that might be predictive of adverse outcomes after transplant. In this highly selected patient population, CCI and HCT-CI scores were low, and these scores were not significantly associated with OS or NRM (data not shown). Falls have been linked with various measures of frailty in the elderly. [17] [18] [19] [20] We asked whether the occurrence of a fall during the transplantation hospitalization might be predictive of adverse outcome after transplant, even in the absence of serious injury related to the fall. We compared the eight patients who fell during hospitalization with the 48 patients who did not. Characteristics of the two groups are shown in Table 5 . There were no differences in sex or CCI and HCT-CI scores between the groups. The rate of readmission within 100 days of transplantation was not significantly different. The median length of stay during the initial hospitalization was 8 days longer in the patients who fell (28 vs 20 days, P ¼ 0.0021), though the median time to neutrophil engraftment was the same (10 days) in each group.
Half of the falls occurred during conditioning, and the other half in the days following stem cell transfusion. The majority occurred at night, typically while getting out of bed or going to the bathroom. One patient had a previous history of dementia. CT scans of the head were obtained in seven of the patients-six were normal and one revealed a subdural hematoma. This patient was asymptomatic and did not suffer any neurological sequelae. No other patients sustained fractures or other injuries that were directly attributed to the fall. Survival analysis, stratified by occurrence of fall, is shown in Figure 2 . Falls were significantly associated with inferior OS (HR 3.36, 95% confidence interval 2.09-29.70, P ¼ 0.0023). Similarly, falls were associated with NRM (HR 4.60, 95% confidence interval 1.86-78.72, P ¼ 0.009). All of the treatment-associated deaths in patients who fell occurred within 1 year after transplantation.
The same analysis was performed using the occurrence of delirium as the grouping variable, rather than falls. Although the incidence of delirium was the same as falls (14%), it was not associated with inferior OS or NRM (data not shown).
Discussion
We describe the OS, NRM and early transplant complications of a series of 56 patients aged 65 years and older who received an auto-SCT for lymphoma, including 17 patients over the age of 70 years. We found that NRM was higher in patients aged 70 years and older compared with those aged 65-69 years (HR 6.04), particularly within the first year (1 year NRM 35 vs 8%, P ¼ 0.0017). There was a trend towards decreased OS (HR 1.98), though this was not statistically significant (P ¼ 0.082). The incidence of inhospital falls was higher in those aged 70 years and older (29 vs 8%, P ¼ 0.047), but no statistically significant differences were seen in rates of delirium, intensive care unit admission, congestive heart failure, readmission rate, length of stay, renal failure and hepatic toxicity. Parameters related to stem cell collection, including median number of cells collected, median number of days to collect adequate cells and time to neutrophil engraftment were similar among both age groups.
There were a number of differences among the baseline characteristics of the patients. Older patients were more likely to be in CR at the time of transplantation (53 vs 18%, P ¼ 0.012), which may reflect more stringent patient selection. Older patients were less likely to die of lymphoma (18 vs 58%), which is likely due to the higher rate of CRs as well as a higher NRM rate. There was a trend towards a higher percentage of women in the older group (53 vs 28%). This is consistent with the observation that women tend to live longer 21 and have fewer comorbidities 22, 23 than men of the same age. Comorbidity as assessed by the CCI and HCT-CI was similar in the two age groups; both groups tended to have very low comorbidity, as would be expected among patients selected for SCT.
A number of other studies have examined outcomes after auto-SCT in patients over the age of 60 or 65 years and compared them to younger patients. Compared with patients less than 60 years old, a cohort of 463 patients aged 60 years and older with diffuse large B-cell lymphoma had higher NRM at 100 days (4.4 vs 2.8%), 1 year (8.7 vs 4.7%) and 3 years (10.8 vs 6.5%; P ¼ 0.002), as well as shorter 3 year progression-free survival (51 vs 62%, Po0.001) and 3 year OS (60 vs 70%, Po0.001). 12 Another study comparing 59 patients aged X60 years and 93 patients age o60 years found a similar increase in treatment-related mortality (; 8.5 vs 5.4%), though this was not statistically significant because of the smaller number of patients. 13 This study also found that CCI score, but not age, was associated with treatment-related mortality (P ¼ 0.03). A third study looked at 93 patients aged X60 years and found similar treatment-related mortality compared with younger patients (5.4 vs 2.2%), but shorter median survival (25 vs 56 months, P ¼ 0.037). 10 In all of these studies, the median age of subjects in the older age group was 63-66 years. To our knowledge, our series is the first to look specifically at patients aged X70 years. There is no consensus regarding the appropriateness of auto-SCT in this older population. Our data indicate that NRM is considerably higher in patients aged X70 years, with a trend towards decreased OS. Nevertheless, we observed a 3 year OS of 44% in these patients, suggesting that auto-SCT may be an appropriate therapy for highly selected patients fit enough to withstand the rigors of myeloablative chemotherapy.
Careful patient selection, therefore, is of paramount importance in older patients. We found that standard comorbidity indices, such as the CCI and HCT-CI, are insufficiently sensitive to accurately select older patients for auto-SCT. Consequently, better tools are needed for pretransplant evaluation of older patients.
In this regard, one suggestive finding from our data is that falls during the transplant admission was strongly associated with higher NRM and inferior OS. Falls in older patients are associated with considerable mortality and morbidity, higher resource utilization, institutionalization and reduced quality of life. [24] [25] [26] [27] Many modifiable risk factors for falls have been evaluated prospectively and are categorized into intrinsic and extrinsic factors. 25, 26, [28] [29] [30] [31] Intrinsic or patient-related risk factors include advanced age, history of previous falls, muscle weakness, gait instability, visual impairment, psychotropic medications, cognitive impairment and factors associated with acute illness such as infection, dehydration or anemia. Extrinsic factors are related to the environment and include medication, poor illumination, inappropriate footwear, high position of bed, unfamiliar obstacles such as walking with an i.v. pole and unfamiliar environment have also been described. 31, 32 Falls usually occur when impairments in multiple domains compromise the individual's ability to adapt to stress. 25, 33 Before transplant, many of the above mentioned risk factors are clinically silent as the patient has sufficient functional and physiologic reserve to maintain their resilience. During the transplant process, an older patient may accumulate additional risk factors, which place them at risk for adverse outcomes such as falls. Falls may be a marker of frailty in these patients, 34 and falls assessment before transplant may help to identify older patients at higher risk of adverse outcomes. Indeed, a recent prospective study of chemotherapy toxicity in the elderly found that a fall in the previous 6 months was an independent predictor of grade 3-5 toxicity. 35 In addition to being a prognostic variable, the occurrence of a fall during transplant may itself lead to adverse outcomes. Patients who experience a fall may become afraid of falling again, which leads them to self-restrict their activities and may diminish psychological resilience. This self-restriction, in turn, leads to decreased muscle strength and postural control, placing these patients at risk for additional falls and other adverse outcomes. [36] [37] [38] It is conceivable than an in-hospital fall could impair recovery from the transplantation procedure and lead to worse outcomes. Screening for falls by performing a multifactorial fall assessment and treating modifiable risk factors, including environmental modifications and medication review, have been shown to reduced falls by 30-40%, 39, 40 and such interventions could be used to reduce fall risk among elderly auto-SCT patients.
Our study has a number of limitations. It was conducted at a single center, and different results might be obtained in other settings. There was a small number of patients in the X70-year old group. There were limited data available on performance status and International Prognostic Index score at diagnosis and at relapse, and therefore it is possible that there were additional imbalances in prognostic factors among the age groups that we were unable to account for. The cause of death was unknown for a number of patients, particularly for those who died more than 3 years after transplant, and we cannot be certain if they died from relapsed lymphoma, treatment-related complications, or other medical problems unrelated to the transplant. It is possible that some transplant-related complications listed in Table 3 may be more common in older patients, but our study did not show a statistically significant association, given the small sample size. In addition, all analyses were unadjusted, precluding the evaluation of confounding relationships between outcomes and baseline patient characteristics. Finally, because of the observational nature of our study, we cannot be certain whether a given patient variable (such as occurrence of a fall) is causative of adverse outcome or simply correlated with it.
In conclusion, we report outcomes after auto-SCT in lymphoma patients over the age of 65 years, the first report with a particular focus on those aged 70 years and older. We found that NRM was significantly higher in patients over age 70 years, with a trend towards decreased OS. Nevertheless, the long-term survival of many of these older patients suggests that auto-SCT should be considered in carefully selected older patients. Better pre-transplant evaluation tools are needed to select those patients most likely to benefit from auto-SCT. Our data indicate that fall risk assessment may identify elderly patients at risk of adverse outcome after auto-SCT. Assessment tools for fall risk, such as the Performance-Oriented Mobility Assessment 41 and the Timed Up-and-Go Test 42 can be performed in under 20 min and could easily be incorporated into the pre-transplant evaluation for older patients. Assessment for frailty 34 could also be performed before transplant and might also predict for adverse outcomes. These and other geriatric assessment tools should be investigated prospectively as a predictor of outcome after auto-SCT in older patients.
